Your browser doesn't support javascript.
Mineralocorticoid Receptor Antagonist (Potassium Canrenoate) Does Not Influence Outcome in the Treatment of COVID-19-Associated Pneumonia and Fibrosis-A Randomized Placebo Controlled Clinical Trial.
Kotfis, Katarzyna; Karolak, Igor; Lechowicz, Kacper; Zegan-Baranska, Malgorzata; Pikulska, Agnieszka; Niedzwiedzka-Rystwej, Paulina; Kawa, Milosz; Sienko, Jerzy; Szylinska, Aleksandra; Wisniewska, Magda.
  • Kotfis K; Department of Anesthesiology, Intensive Therapy and Acute Intoxications, Pomeranian Medical University, 70-111 Szczecin, Poland.
  • Karolak I; Department of Anesthesiology, Intensive Therapy and Acute Intoxications, Pomeranian Medical University, 70-111 Szczecin, Poland.
  • Lechowicz K; Department of Anesthesiology, Intensive Therapy and Acute Intoxications, Pomeranian Medical University, 70-111 Szczecin, Poland.
  • Zegan-Baranska M; Department of Anesthesiology, Intensive Therapy and Acute Intoxications, Pomeranian Medical University, 70-111 Szczecin, Poland.
  • Pikulska A; Department of Anesthesiology, Intensive Therapy and Acute Intoxications, Pomeranian Medical University, 70-111 Szczecin, Poland.
  • Niedzwiedzka-Rystwej P; Institute of Biology, University of Szczecin, 71-412 Szczecin, Poland.
  • Kawa M; Department of Radiology, Pomeranian Medical University, 70-111 Szczecin, Poland.
  • Sienko J; Department of General and Transplantation Surgery, Pomeranian Medical University, 70-111 Szczecin, Poland.
  • Szylinska A; Department of Medical Rehabilitation and Clinical Physiotherapy, Pomeranian Medical University, 71-111 Szczecin, Poland.
  • Wisniewska M; Clinical Department of Nephrology, Transplantology and Internal Medicine, Pomeranian Medical University, 70-111 Szczecin, Poland.
Pharmaceuticals (Basel) ; 15(2)2022 Feb 05.
Article in English | MEDLINE | ID: covidwho-1690192
ABSTRACT
In December 2019 the SARS-CoV-2 virus appeared in the world, mainly presenting as an acute infection of the lower respiratory tract, namely pneumonia. Nearly 10% of all patients show significant pulmonary fibrotic changes after the infection. The aim of this study was to evaluate the effectiveness and safety of potassium canrenoate in the treatment of COVID-19-associated pneumonia and pulmonary fibrosis. We performed a randomized clinical trial (RCT) of potassium canrenoate vs placebo. A total of 55 patients were randomized and 49 were included in the final analysis (24 allocated to the intervention group and 25 allocated to the control group). Patients were assessed by physical examination, lung ultrasound, CT imaging and blood samples that underwent biochemical analysis. This RCT has shown that the administration of potassium canrenoate to patients with COVID-19 induced pneumonia was not associated with shorter mechanical ventilation time, shorter passive oxygenation, shorter length of hospitalization or less fibrotic changes on CT imaging. The overall mortality rate was not significantly different between the two groups. Adverse events recorded in this study were not significantly increased by the administration of potassium canrenoate. The negative outcome of the study may be associated with the relatively small number of patients included. Any possible benefits from the use of potassium canrenoate as an antifibrotic drug in COVID-19 patients require further investigation.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Controlled clinical trial / Observational study / Randomized controlled trials / Risk factors Language: English Year: 2022 Document Type: Article Affiliation country: Ph15020200

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Controlled clinical trial / Observational study / Randomized controlled trials / Risk factors Language: English Year: 2022 Document Type: Article Affiliation country: Ph15020200